

	Covid-19 ICU non-CIN/CIM matched (n=7)	<i>P</i>
Gender, <i>male</i> n (%)	6 (86)	0,16
Age, <i>yrs</i>	51 (46-58)	0,12
BMI	33 (29-39)	0,79
ACEi/ARB treatment (%)	2 (29)	0,47
Comorbidities, n (%)		
Pulmonary disease	1 (14)	0,83
Hypertension	2 (29)	0,14
Heart failure	0 (0)	0,14
Peripheral vessel disease	1 (14)	0,51
Diabetes mellitus	3 (43)	0,78
Neurological disease	1 (14)	0,16
Malignancy	0 (0)	1

**Supplementary table 1.** Demographics for 7 intubated COVID-19 patients treated > 12 days in the intensive care unit (ICU) who did not develop critical illness neuropathy or myopathy (CIN/CIM) and from whom plasma samples were analysed for neurofilament light chain (NFL), tau and glial fibrillary acidic protein (GFAP). ACEi – Angiotensin Converting Enzyme inhibitor; ARB – Angiotensin Receptor Blocker. Values are represented as median (IQR) or n (%). The p-value originates from comparisons with CIN/CIM-group using the Mann-Whitney U test for continuous parameters and the chi-square test for categorical parameters. Values are represented as median (IQR) or n (%).

	<i>n</i>	Covid-19 ICU CIN/CIM matched	<i>P</i>
<b>On admission</b>			
SAPS	7	49 (48-54)	0.96
Respiratory rate (breaths per minute)	7	28 (22-32)	0.48
Mean arterial blood pressure (mmHg)	7	86 (82-94)	0.89
Heart rate (beats per minute)	7	93 (90-102)	0.50
Body temperature (degrees Celsius)	7	38.4 (37.4-39.0)	0.75
Days with COVID-19	7	10 (10-11)	0.34
<b>In the ICU</b>			
Length of stay	7	18 (17-21)	0.13
Thromboembolic events	7	2 (33)	0.47
Invasive ventilation (%)	7	7(100)	1
Invasive ventilation free days	7	18 (17-19)	<0.001
Vasoactive medication (%)	7	7 (100)	1
Vasoactive medication free days	7	20 (18-22)	0.03
Renal replacement therapy (RRT, %)	7	1 (14)	0.03
RRT free days	1	21 (21-21)	1
Continuous propofol anaesthesia (%)	7	7 (100)	1
Propofol anaesthesia free days	7	16 (15-17)	0.08
Iv Opioid analgesia (%)	7	7 (100)	1
Iv Opioid analgesia free days	7	14 (8-17)	0.06
Continuous iv neuromuscular blockade (%)	7	7 (100)	1
Iv neuromuscular blockade free days	7	24 (20-26)	0.10
ICU-mortality (%)	7	0 (0)	0.07
30-day mortality (%)	7	0 (0)	0.15

**Supplementary table 2. Clinical data for 7 intubated COVID-19 patients treated > 12 days in the intensive care unit (ICU) who did not develop critical illness neuropathy or myopathy (CIN/CIM) and from whom plasma samples were analysed for neurofilament light chain (NFL), tau and glial fibrillary acidic protein (GFAP).** Opioid analgesia includes morphine, oxycodone, remifentanil and/or fentanyl. Neuromuscular blockade includes rocuronium or atracurium. Values are represented as median (IQR) or n (%). The p-value originates from comparisons with CIN/CIM-group using the Mann-Whitney U test for continuous parameters and the chi-square test for categorical parameters. Values are represented as median (IQR) or n (%).

